The Motley Fool··Jonathan PoncianoEyePoint Pharmaceuticals Attracts $20M Strategic Investment Amid 93% Annual Surge
Parkman Healthcare Partners invests $20M in EyePoint Pharmaceuticals as shares surge 93% annually ahead of mid-2026 Phase 3 data for retinal disease treatment DURAVYU.
CVSDXCMEYPTPODDbiotechPhase 3 trials